

Human Metabolome Technologies, Inc. (HMT) Expands to U.S., Opens Office in Cambridge, Mass.

Proximity to world-class institutions and pharmaceutical companies for cancer and biomarker research makes Cambridge the top choice for HMT.

Cambridge, Mass., November 1, 2012 – Human Metabolome Technologies, Inc. (HMT), the leading provider of capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technology, today announced the opening of its first U.S. office in Cambridge, Mass.

The location of the office was based largely in part by the accessibility for globally competitive pharmaceutical companies and research institutions to HMT's most important metabolome analysis services, CARCINOSCOPE, which was specifically designed for cancer research, and BASIC SCAN for more global, general-purpose metabolomics research including biomarker discovery and companion diagnostics.

“Cambridge provides the perfect combination of academic and industrial arenas especially associated with the field of life science, food engineering, and environmental studies,” said Tsutomu Hoshiba, President, HMT America. “HMT provides cutting-edge solutions to life scientists, medical doctors, and pharmacologists via our state-of-the-art metabolomics technology based on capillary electrophoresis mass spectrometry (CE-MS), and we believe that Cambridge is the place to be for networking with businesses who will make the most of our solutions.”

About Human Metabolome Technologies

Human Metabolome Technologies, Inc. (HMT) is a Japan-based biotechnology company providing capillary electrophoresis mass spectrometry based metabolomics services. HMT's primary business aims to provide complete solutions for metabolomics research in biomarker discovery, drug design, diagnostic technology, and food production. HMT was founded in July 2003 by Professor Masaru Tomita, Ph.D., Director of the Institute for Advanced Biosciences (IAB), Keio University, Japan, and by IAB's Professor Tomoyoshi Soga, Ph.D. The company has been awarded government funding from the New Energy and Industrial Technology Development Organization. HMT has also established a number of partnerships, including Agilent Technologies, Inc., Mizkan Group Corporation, Ajinomoto Co., Inc., and Mitsubishi Pharma Corporation in Japan.

HMT America contact:

Tsutomu Hoshiba

hoshiba@humanmetabolome.com

617-987-0554